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Available online xxxxBackground:Mitral valve prolapse syndrome (MVPS) and MASS phenotype (MASS) are Marfan-like syndromes
that exhibit aortic dilatation andmitral valve prolapse. Unlike inMarfan syndrome (MFS), the presence of ectopia
lentis and aortic aneurysm preclude diagnosis of MVPS and MASS. However, it is unclear whether aortic dilata-
tion and mitral valve prolapse remain stable in MVPS or MASS or whether they progress like in MFS.
Methods: This retrospective longitudinal observational study examines clinical characteristics and long-term
prognosis of 44 adults withMVPS orMASS (18men, 26 women aged 38± 17 years) as comparedwith 81 adults
with Marfan syndrome (MFS) with similar age and sex distribution. The age at ﬁnal contact was 42 ± 15 years
with mean follow-up of 66 ± 49 months.
Results:At baseline, ectopia lentis and aortic sinus aneurysmwere absent inMVPS andMASS, and systemic scores
deﬁned by the revised Ghent nosology were lower than in MFS (all P b .001). Unlike in MFS, no individual with
MVPS andMASS developed aortic complications (P b .001). In contrast, the incidence of endocarditis (P= .292),
heart failure (P= .644), andmitral valve surgery (P= .140)was similar in all syndromes. Cox regression analysis
identiﬁed increased LV end-diastolic (P = .013), moderate MVR (P = .019) and ﬂail MV leaﬂet (P = .017) as
independent predictors of mitral valve surgery.
Conclusions: The study provides evidence thatMVPS andMASS areMarfan-like syndromeswith stability of aortic
dilatation but with progression ofmitral valve prolapse. Echocardiographic characteristics ofmitral valve disease
rather than the type of syndrome, predict clinical progression of mitral valve prolapse.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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FBN11. IntroductionModern echocardiographic criteria identify mitral valve (MV) pro-
lapse (MVP)with systolic prolapse N2mmofMV leaﬂets, andwith leaf-
let thickening ≥5 mm during diastole. MVP is non-classic with isolated
presence of leaﬂet prolapse and classic when combined with leaﬂet
thickening [1]. Classic and non-classic MVP together have a prevalence
of 2.4% in the general population [1].ability and freedom from bias of
amburg-Eppendorf, Hamburg,
).
land Ltd. This is an open access articlSome individuals withMVP develop severe MV regurgitation, endo-
carditis, heart failure, and sudden cardiac death [2]. MVPmay occur as a
familial, and non-familial trait andMVP canmanifestwith syndromic or
non-syndromic phenotype [3]. The etiology of MVP is largely unknown.
Several ﬁndings argue for involvement of genetic factors in the patho-
genesis ofMVP: (1) some families withMVP exhibit X-linked or autoso-
mal dominant inheritance with incomplete penetrance [3], (2) genetic
studies showed linkage of MVP to chromosomes 3q31.3–q32.1,
11p15.4, and 16p12.11–p11.2, (3) some MVP phenotypes are caused
by mutations in the X-linked ﬁlamin A gene (FLNA) [3,4], or in DCHS1
[5], and (4) MVP is an established cardiovascular feature of several ge-
netic aortic disorders including Marfan syndrome (MFS), Loeys–Dietz
syndrome, aneurysmosteoarthritis syndrome, and thoracic aortic aneu-
rysms caused by mutations in the TGFB2 and SMAD3 genes [6]. In this
study we examined MVP in Marfan-like syndromes comprising MVP
syndrome (MVPS) and MASS phenotype (MASS).e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics in 125 adults with various syndromic forms of mitral valve
prolapse.
Variablea MVPS
(N = 29)
MASS
(N = 15)
MFS
(N = 81)
Pb
Age at initial evaluation (years) 42 ± 19 30 ± 11 35 ± 12 .093
Male gender 14 (48%) 4 (27%) 34 (42%) .399
Total cholesterol (mg/dl) 194 ± 39 207 ± 47 187 ± 40 .366
HDL cholesterol (mg/dl) 58 ± 15 74 ± 22 55 ± 16 .042
LDL cholesterol (mg/dl) 113 ± 27 117 ± 31 107 ± 36 .406
Systolic blood pressure
(mm Hg)
132 ± 17 125 ± 16 126 ± 16 .302
Diastolic blood pressure
(mm Hg)
75 ± 11 73 ± 14 73 ± 10 .521
BAB medication 8 (28%) 2 (13%) 40 (49%) .009
ACEi or ARB medication 3 (10%) 0 17 (21%) .087
Previous ischemic neurologic
event
2 (7%) 0 4 (5%) .687
Ectopia lentis 0 0 38 (47%) b.001
Systemic score (points) 1.1 ± 1.3 7.2 ± 3 7.3 ± 3.5 b.001
Aortic sinus diameter (cm) 3 ± .4 2.9 ± .4 4.5 ± 3 b.001
Aortic sinus Z-score −.8 ± 1.3 −.8 ± 2.1 3.7 ± 2.9 b.001
LV ejection fraction (%) 59 ± 11 58 ± 8 57 ± 11 .900
Indexed LVESD (mm/m2) 17 ± 4 18 ± 3 17 ± 4 .788
Indexed LVEDD (mm/m2) 27 ± 4 27 ± 3 27 ± 4 .966
Indexed left atrial diameter
(mm/m2)
21 ± 6 18 ± 3 19 ± 4 .240
Anterior MV leaﬂet prolapsec 22/28 (79%) 11/13 (85%) 75/80 (94%) .060
Posterior MV leaﬂet prolapsec 15/28 (54%) 2/13 (15%) 53/80 (66%) .002
Bileaﬂet MVPc 11/28 (39%) 1/13 (8%) 48/80 (60%) b.001
MV bileaﬂet thickening 9/26 (35%) 4/13 (31%) 14/80 (18%) .151
Moderate degree of MVR 11 (38%) 4 (27%) 13 (16%) .049
Flail MV leaﬂet 3 (10%) 0 4 (5%) .488
Tricuspid valve prolapse 3/27 (11%) 1/13 (8%) 26/79 (33%) .022
NT-proBNP (pg/ml) 67 ± 63
(N = 7)
100 ± 100
(N = 7)
842 ± 2249
(N= 48)
.003
ACEi identiﬁes angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor
blockers; BAB, beta-adrenergic blockers; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; LV, left ventricle; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic
diameter; MASS, MASS phenotype; MV, mitral valve; MVR, mitral valve regurgitation;
MVPS, mitral valve prolapse syndrome; MFS, Marfan syndrome; np, not performed; NT-
pro-BNP, N-terminal pro-brain natriuretic peptide.
a Continuous data are presented as mean ± standard deviation.
b Kruskal–Wallis test for continuous data and the generalized Fisher's exact test for
nominal and categorical data.
c We excluded 1 individual withMVPS and MFS, respectively, and 2 individuals with
MASS because in these documentations MVP was available without original echocar-
diographic documentation; we included 2 individuals with MVPS and 1 with MASS,
who had original echocardiographic documentation which described buckling of a
single MV leaﬂet according to Freed without speciﬁcation of MV leaﬂet. We consid-
ered mono-leaﬂet MVP in these 3 individuals, but we counted prolapse as absent in
both the anterior and the posterior MV leaﬂet.
40 M. Rippe et al. / IJC Heart & Vasculature 10 (2016) 39–46Early descriptions of MVPS suggested atypical chest pain, exertional
dyspnea, palpitations, syncope, anxiety, low blood pressure, lean body
stature, and electrocardiographic repolarization abnormalities as typical
features of MVPS [2], but of these only leaner bodymass was conﬁrmed
in population-based cohorts [2,7]. Today, the revised version (Ghent-2)
[8] of the initial Ghent nosology (Ghent-1) [9,10] deﬁnes MVPS as MVP
with Marfan-like features including pectus excavatum, scoliosis and
arachnodactyly, but with a systemic score on the Ghent-2 nosology b5
points [8]. The Ghent-2 systemic score considers 13 manifestations ac-
cording to their diagnostic accuracy for MFS comprising MVP, myopia,
skeletal manifestations, pneumothorax, dural ectasia, and skin striae.
In addition, diagnosis of MVPS requires exclusion of aortic root aneu-
rysm Z-scores ≥2 and of ectopia lentis [8].
In 1989 Glesby and Pyeritz suggested the acronym “MASS” to de-
scribe phenotypes involving MV, aorta, skeleton, and skin [11]. They
suggested that individuals with the exclusion of ectopia lentis, with
only mild dilatation of the aortic root and with Marfan-like manifesta-
tions including MVP, skeletal features, and skin striae should be diag-
nosed as having MASS [11]. In 1996 the Ghent-1 nosology revised
MASS criteria as presence of myopia, MVP, mild aortic dilatation, skin
striae, and minor skeletal involvement, where diagnosis required in-
volvement of ≥2 different organ systems [9]. Similar to MVPS, the cur-
rent Ghent-2 nosology redeﬁned MASS with the presence of MVP and
some Marfan-like clinical features and with exclusion of aortic root an-
eurysm (≥2 Z-scores) and of ectopia lentis. In contrast to MVPS the def-
inition of MASS requires a systemic score ≥5 points. The etiology of
MASS remains unknown, although some causative ﬁbrillin-1 (FBN1)
mutations presentedwithMASS phenotype [12]. FBN1mutations usual-
ly cause MFS which carries a high risk for rupture and dissection of the
aorta. Some authors consider MASS as the mild end of a continuous
spectrum of Marfan-like syndromes [13]. However, detection of a caus-
ative FBN1mutation inMASS raised concerns aboutMASS to evolve into
outright MFS and overt dissection or rupture of the aorta [8,14].
Today, there is only scarce clinical data on MVPS [15–17] and MASS
[11,12,14,18–21], and there is no study to assessMVPS orMASSwith re-
cent Ghent-2 criteria. Moreover, prognosis of MVP and aortic disease in
MVPS and MASS has not been described. Hence, the Hamburg and
Ghent Marfan centers joined to perform a retrospective longitudinal,
observational study with the aim to characterize the clinical features
of these entities by applying the current Ghent-2 criteria. Furthermore
we studied the long-term outcomes of cardiovascular manifestations
ofMVPS andMASS in comparisonwithMFS.Wewanted to testwhether
MVPS andMASS remained unaffected by aortic root complications, and
we aimed to examine whether MVP evolved with similar severity as
known in MFS, where MVP tends to be progressive [22–24].
2. Methods
2.1. Patients
We screened patient records for individuals aged 18 years or older
who exhibited MVP diagnosed in MVPS or in MASS, and we compared
these with individuals of the same age who exhibited MVP related to
MFS. We identiﬁed a total of 44 adults with MVPS or MASS of whom
18 were men and 26 were women at a mean age of 38 ± 17 years
(range 18–70 years), and 81 adults with MFS, including 34 men and
47 women at a mean age of 35 ± 12 years (range 18–67 years). We
identiﬁed 80 of these patients in Hamburg and 45 patients in Ghent.
We applied Ghent-2 criteria to establish the ﬁnal diagnosis of MVPS,
MASS and MFS [8]. In brief, MVPS was present with MVP, exclusion of
aortic root dilatation with Z-scores ≥2, ectopia lentis, and exclusion of
a systemic score ≥5 points. Similarly, MASS was present with MVP, ex-
clusion of aortic root dilatation ≥2 Z-scores and ectopia lentis, but
with a systemic score ≥5 points including at least one skeletal feature.
MFS was conﬁrmed, ﬁrst in the absence of a family history of MFS,
with aortic root dilatation (Z-scores ≥2) and ectopia lentis, or withsystemic score ≥7 points, or with ectopia lentis and a FBN1 mutation
known to cause aortic dilatation, and second, in the presence of a family
history, with ectopia lentis, or with systemic score ≥7 points, or with
aortic root dilatation (Z-scores ≥ 2) [8]. All individuals withMFS fulﬁlled
clinical criteria and harbored a causative FBN1mutation [8].We veriﬁed
the diagnosis ofMVPS andMASS clinically in all individuals at the age of
N20 years [8], andwe did not ﬁnd a causative FBN1mutation in all these
individuals. As Ghent-2 recommends, we diagnosedMVPwith the pres-
ence of ≥1 of the echocardiographic standard criteria as speciﬁed below
[8,25].
2.2. Genetic analysis
We extracted DNA from EDTA blood samples using standard proce-
dures, and ampliﬁed the coding region and ﬂanking intronic sequences
including 20nucleotides of the introns at each acceptor (positions−1 to
−20) and donor splice site (positions +1 to +20) of the FBN1, (NM
000138.4), TGFBR1 (NM 004612.2) and TGFBR2 (NM 001024847.2)
genes by PCR in all patients. We performed Sanger sequencing of the
PCR products with an ABI PRISM 310 Genetic analyzer using the ABI
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[26,27]. To detect single and multiple exon deletions or duplications,
we used 100 ng DNA for multiplex ligation-dependent probe ampliﬁca-
tion (MLPA) [28] with SALSA kits P065 (probes for FBN1 and TGFBR2)
and P066 (probes for FBN1) (MRC Holland, Amsterdam, The
Netherlands) according to the manufacturer's protocol. We separated
PCR products on an ABI PRISM 310 or 3130xl Genetic analyzer (Applied
Biosystems), and we analyzed MLPA results with the Sequence Pilot al-
gorithm (JSI Medical Systems, Kippenheim, Germany).
2.3. Baseline characteristics
At the time of initial evaluation at our institutions, we obtained age,
sex, body surface area according to Du Bois [29], fasting blood lipid
levels, and systolic and diastolic blood pressure after 15-min rest on
standard sphygmomanometer [30]. We documented intake of beta-
blockers (BAB), angiotensin-converting enzyme inhibitors (ACEi), or
angiotensin-receptor blockers (ARB) with medication over ≥1 year
prior to baseline, previous ischemic neurologic events with cerebral in-
farction identiﬁed as persistence of a focal neurologic deﬁcit for ≥24 h
caused by altered cerebral circulation shown on tomographic images
or with transient ischemic attack with resolution of a focal neurologic
deﬁcit ≤24 h [23,31]. Ectopia lentis was present with any displacement
of the lenses, or after surgery for this condition, and we assessed wrist
sign, thumb sign, pectus carinatum, pectus excavatum, chest asymme-
try, hindfoot deformity, plain pes planus, protrusio acetabuli, reduced
upper segment/lower segment ratio, increased arm/height ratio, scolio-
sis or thoracolumbar kyphosis, reduced elbow, extension, facial features,
pneumothorax, dural ectasia, skin striae, myopia N−3 diopters, and
MVP in all individuals to calculate the Ghent systemic score [8,32].
We used standard 2-dimensional transthoracic echocardiographic
recordings to assess aortic root diameters in the parasternal long-axis
view at the level of the aortic sinuses at end-diastole using the
leading-edge method with calculation of Z-scores using Devereux's for-
mula [33], left ventricular (LV) ejection fraction according to Simpson
[34], LV end-systolic diameters (LVESD), LV end-diastolic diameters
(LVEDD), and left atrial diameters with normalization to BSA according
to current guidelines [34].We assessed prolapse ofMV leaﬂets separate-
ly with posterior and anterior late systolic prolapse N2mm onM-mode
echocardiography, or on two-dimensional echocardiography from the
parasternal long-axis view as leaﬂet displacement N2 mm, where we
also measured the displacement of this leaﬂet in the apical four-
chamber view; however, because of the lateral scallop of the posterior
leaﬂet is most difﬁcult to evaluate from these views, we conﬁrmed the
degree of displacement always by examination of the long-axis scansTable 2
Clinical events in 125 patients with mitral valve prolapse.
Outcome variablesa Age at event
(years; range)
MVPS
(N = 31)
Age at baseline (years) 36 ± 14 (18–70) 42 ± 19 (18
Age at ﬁnal contact (years) 42 ± 15 (21–79) 47 ± 20 (21
Follow-up interval (months) 66 ± 49 (1–183) 50 ± 41 (1–
Patients lost to follow-up 24 ± 3 (22–28) 1 (3%)
Non-MV-related clinical events
– Death 56 ± 20 (34–77) 1 (3%)
– Aortic surgeryc 39 ± 12 (19–69) 0
MV-related clinical events
–MV endocarditis 32 ± 9 (19–39) 0
– Heart failure 51 ± 14 (31–72) 3 (10%)
–MV surgeryd 44 ± 15 (21–72) 6 (21%)
– Patients with MV-related events 45 ± 16 (19–72) 8 (28%)
MV identiﬁes mitral valve.
a Continuous data are presented as mean ± standard deviation.
b For comparison between all three groups we employed the Kruskal–Wallis test for continu
c Aortic surgery comprised composite valve grafting according to Bentall, aortic valve-sparin
placement of a stent-graft in the descending thoracic aorta.
d MV surgery comprised replacement of the MV or surgical reconstruction procedures.[1]. We consideredMV leaﬂet thickeningwith a thickness ≥5mm sepa-
rately for both mitral leaﬂets during diastasis.We consideredMVPwith
displacement N2 mm of at least one MV leaﬂet. We quantiﬁed MV re-
gurgitation asmoderate (we did not see individuals with severeMV re-
gurgitation at baseline), and we assessed ﬂail mitral leaﬂet, and
tricuspid valve prolapse according to current guidelines. In addition,
we measured N-terminal pro-brain natriuretic peptide (NT-proBNP)
serum levels with an electrochemiluminescence sandwich immunoas-
say (Roche Diagnostics GmbH, Mannheim, Germany) on the Elecsys
System 2010 with a detection limit ≥5 pg/ml (Table 1) [35].2.4. Clinical events
We assessed all MV-related clinical events during clinical evaluation
at our institutions and upon interviews during follow-up, where we
documented both the age of initial occurrence of each clinical event,
and the time interval between the initial evaluation at our institutions
and the ﬁnal contact. We considered clinical events as related to the
MV only with documentation of clinical and echocardiographic criteria
of infective endocarditis involving the MV, heart failure related to the
MVwith clinical signs and symptoms of congestive heart failure accord-
ing to classical criteria [36], and surgery of the MV that was performed
as an isolated procedure for severe MVR as diagnosed by echocardio-
graphic standard criteria in all patients. Finally, we assessed aortic sur-
gery or intervention, and death with unknown cause (Table 2).
2.5. Statistical methods
We performed an exploratory data analysis and therefore we made
no adjustments for multiple testing.We compared baseline characteris-
tics with the Kruskal–Wallis test for continuous data and the general-
ized Fisher's exact test for nominal and categorical data (Tables 1 and
2). For time-to-event analysis of study variables with MV surgery we
performed univariable Cox regression analysis and we included vari-
ables with P b .05 in a multivariable Cox regression model with back-
ward elimination to determine independent predictors of prognosis
within these sets (Table 3). To investigate the inﬂuence of age assessed
from birth to the time of MV surgery depending on MV morphologic
characteristics, we used the Kaplan–Meier estimator to calculate the cu-
mulative probability of event displayed as 1 — the cumulative event-
free functions, and with the Log rank to screen for statistical differences
(Fig. 3). We considered P-values as descriptive measures with values
b.05 only as an indicator of inhomogeneity between groups. Unless oth-
erwise speciﬁed, we expressed quantitative data as means ± standardMASS
(N = 13)
MFS
(N = 81)
Pb
–70) 30 ± 11 (19–51) 35 ± 12 (18–67) .093
–79) 35 ± 12 (22–55) 42 ± 13 (21–72) .095
151) 58 ± 42 (1–135) 73 ± 51 (1–183) .134
2 (15%) 1 (1%) .037
0 4 (5%) 1.000
0 35 (43%) b.001
1 (7%) 3 (4%) .292
0 8 (10%) .644
0 16 (20%) .140
1 (7%) 21 (26%) .227
ous data and the generalized Fisher's exact test for nominal and categorical data.
g re-implantation techniques according to David, wrapping of the ascending aorta, and
Table 3
Predictors of mitral valve surgery as outcome.
Variable Hazard
ratio
Lower
95% CI
Upper
95% CI
Pa
Age at initial evaluation (years) 1.028 1.000 1.058 .051
Male gender 1.582 .681 3.675 .285
Body surface area (m2) .254 .037 1.722 .160
Total cholesterol (mg/dl) 1.003 .992 1.014 .633
HDL cholesterol (mg/dl) .987 .957 1.017 .386
LDL cholesterol (mg/dl) 1.002 .989 1.016 .724
Systolic blood pressure (mm Hg) 1.001 .975 1.027 .953
Diastolic blood pressure (mm Hg) .968 .928 1.010 .130
BAB medication 1.150 .488 2.710 .749
ACEi or ARB medication .485 .130 1.806 .281
Previous ischemic neurologic event .045 .000 143.969 .451
Ectopia lentis .725 .282 1.862 .503
Systemic score (points) .885 .782 1.000 .051
Aortic sinus diameter (cm) .753 .461 1.228 .256
Aortic sinus Z-score .924 .810 1.055 .242
LV ejection fraction (%) .975 .939 1.012 .184
Indexed LVESD (mm/m2) 1.094 1.014 1.181 .021
Indexed LVEDD (mm/m2) 1.159 1.076 1.247 b.001
Indexed left atrial diameter (mm/m2) 1.142 1.068 1.229 b.001
Anterior MV leaﬂet prolapse .383 .126 1.160 .090
Posterior MV leaﬂet prolapse 12.734 1.700 95.400 .013
Bileaﬂet MV prolapse 2.493 .908 6.845 .076
MV bileaﬂet thickening 2.734 1.127 6.630 .026
Moderate degree of MV regurgitation 4.518 1.778 11.482 .002
Flail MV leaﬂet 5.015 1.802 13.959 .002
Tricuspid valve prolapse 2.157 .910 5.114 .081
MVPS/MASS vs MFS .725 .274 1.921 .518
ACEi identiﬁes angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor
blockers; BAB, beta-adrenergic blockers; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; LV, left ventricle; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic
diameter; MASS, MASS phenotype; MV, mitral valve; MVR, mitral valve regurgitation;
MVPS, mitral valve prolapse syndrome; and MFS, Marfan syndrome.
a Univariate Cox regression analysis.
42 M. Rippe et al. / IJC Heart & Vasculature 10 (2016) 39–46deviation and qualitative data as numbers (percentage). We used
IBM-SPSS software (IBM Corp. Released 2013. IBM SPSS Statistics for
Windows, Version 22.0. Armonk, NY: IBM Corp) for all statistical tests.Fig. 1. Analysis of systemic features comprising wrist/thumb sign, chest deformity, pes planus, p
elbow extension, facial features (3/5), skin striae, andmyopia N3 diopters as deﬁned in the Ghen
signs, wherewe identiﬁed 6, 57 and 234 systemic signs in 11, 13 and 59 individuals withmitral
respectively. We present the frequency of each clinical feature relative to the total number of f3. Results
3.1. Baseline characteristics
MVPS andMASS were unrelated to FBN1, TGFBR1 and TGFBR2muta-
tions in all individuals. Age, sex, lipid levels, blood pressures and medi-
cation were similar in all groups, but BAB medication was less frequent
in MVPS andMASS (P= .009), and systemic score points were lower in
MVPS and MASS than in MFS (P b .001; Figs. 1 and 2). Moderate MV
regurgitation was somewhat more prevalent in MVPS than in MFS
(P = .049), but tricuspid valve prolapse was less frequent in MVPS
and MASS than in MFS (P = .022). NT-pro-BNP levels were lowest in
MVPS, higher in MASS and highest in MFS (P= .003; Table 1).
3.2. Clinical events
The average age at baseline evaluationwas 36±14 years. The age at
ﬁnal contact was 42± 15 years, where only 4 individuals were lost dur-
ing 65 ± 48 months of follow-up. Death occurred in four individuals
with MFS where severe aortic disease was the most likely cause of
death, and in one individual with MVPS where the cause of death was
unclear. In contrast to MFS, no single individual with MVPS or MASS re-
quired aortic surgery or intervention (P b .001). Conversely, the inci-
dence of endocarditis (P = .292), heart failure (P = .644), and MV
surgery (P= .140) was similar in all syndromes.
Kaplan–Meier curve analysis showed that at the age of 47 years al-
ready 51% ofMFS had undergone aortic surgery or intervention, where-
as no individual with MVPS or MASS required aortic surgery (P b .001).
In contrast, 56% had undergone MV surgery at the age of 69 years with
MVPS or MASS as compared with 58% at the age of 58 years with MFS
(P= .168; Fig. 3).
3.3. Predictors of MV surgery
Cox regression analysis identiﬁed that the risk for the need of MV
surgery was related to increased indexed LV end-systolic (P.021), LV
end-diastolic (P b .001), and left atrial diameters (P b .001), posteriorneumothorax, dural ectasia, growth/anthropometric features, scoliosis/kyphosis, reduced
t-2 nosology [8].We only present results from individuals with complete assessment of all
valve prolapse syndrome (MVPS), MASS phenotype (MASS), andMarfan syndrome (MFS),
eatures found in each syndrome (percent).
43M. Rippe et al. / IJC Heart & Vasculature 10 (2016) 39–46MVP (P = .013), MV bi-leaﬂet thickening (P = .026), moderate MV
regurgitation (P = .002), and ﬂail mitral leaﬂet (P = .002; Table 3).
Multivariate Cox regression analysis of all univariately signiﬁcant vari-
ables identiﬁed that increased LV end-diastolic (HR = 1.118; 95% CI
1.023–1.222; P = .013), moderate MVR (HR = 3.146; 95% CI
1.207–8.199; P = .019) and ﬂail MV leaﬂet (HR = 3.698; 95% CI
1.265–10.808; P= .017) as independent predictors of MV surgery.
4. Discussion
With the application of current Ghent-2 criteria and with no evi-
dence of a causative mutation in FBN1, TGFBR1 and TGFBR2, our study
provides novel insights into the clinical characteristics and long-term
prognosis of MVPS and MASS. As expected, MVPS- and MASS-affected
individuals exhibited similar systemic features as those with MFS.Fig. 2. The box-and-whisker plots of aortic sinus diameters (upper panel) and of aortic sinu
(2.2–3.7 cm) in MVPS, 2.8 cm (2.1–3.6 cm) in MASS, and 4.1 cm (2.5–7.4 cm) in MFS (P b .0
−.97 (−4.22–3.14) in MASS, and 3.6 (−.377–10.46) in MFS (P b .001).Unlike inMFS, no individual withMVPS orMASS developed aortic com-
plications. In contrast, the incidence of endocarditis, heart failure, and
MV surgery was similar in all syndromes. The risk for MV surgery
depended exclusively on the presence of classical echocardiographic
predictors of MV disease progression such as LV diameters andMV dys-
function at baseline.
The diagnostic criteria of MVPS and MASS underwent substantial
changes since their initial description [11,17,37]. These changes may
be explained by a combination of factors that have signiﬁcantly evolved
over time: molecular testing has become more widely available and
now plays a more important role in the new nosology as compared
with the initial Berlin nosology [10,38], more reliable 2D echocardiogra-
phy has replaced the former M-mode echocardiography to diagnose
MVP [39], and new entities such as the Loeys–Dietz syndrome caused
by TGFBR1 or TGFBR2 mutations have been added to the phenotypics Z-scores (lower panel). The median and range of aortic sinus diameters were 3.0 cm
01). The median and range of aortic sinus Z-scores were−.47 (−4.11–1.02) in MVPS,
44 M. Rippe et al. / IJC Heart & Vasculature 10 (2016) 39–46spectrum of Marfan-like syndromes [40]. We applied modern diagnos-
tic criteria and excluded individuals carryingmutations in FBN1, TGFBR1
and TGFBR2 in MVPS andMASS, because thesemutations are associated
with a high risk for aortic aneurysm and dissection, or their carriersmay
develop outright MFS or LDS [14]. Moreover, we accepted MVPS and
MASS only with aortic Z-scores b2. Finally, as the MFS phenotype mayFig. 3. Kaplan–Meier curve analysis comparing the cumulative probability for clinical events
versus individuals with Marfan syndrome (MFS) according to age. The upper panel analyse
cumulative probability for mitral valve surgery.emerge with age we only considered individuals as having MVPS and
MASS with conﬁrmation of the diagnosis at an age N20 years. These
rigid diagnostic policies may explain the distinct long-term prognosis
of MVPS and MASS as compared with MFS.
Our study identiﬁed Marfan-like skeletal features, skin striae, and
primary spontaneous pneumothorax inMVPS. The literature conﬁrmedin individuals with mitral valve prolapse syndrome (MVPS) or MASS phenotype (MASS)
s the cumulative probability for aortic root surgery, and the lower panel analyses the
45M. Rippe et al. / IJC Heart & Vasculature 10 (2016) 39–46striae and Marfan-like skeletal manifestations in MVPS, differing from
MFS only in their frequency and severity [11,17]. Similarly, some studies
conﬁrmed pneumothorax inMVPS [41,42]. InMVPS we did not identify
dural ectasia, and we also did not ﬁnd studies to report on this associa-
tion. Similarly, patients with MVPS did not exhibit myopia N3 diopters.
One study reports a high prevalence ofmildmyopiawith an average of 2
diopters in MVPS [43]. We found that all systemic features of MFS also
were present in MASS, which corroborates ﬁndings from the initial de-
scription of this phenotype [11]. Systemic score points did not relate to
MV-related events.
Two reasons may explain why we did not observe aortic complica-
tions in MVPS and MASS. First, we carefully excluded mutations in
genes that are associated with a high risk for aneurysm, dissection or
rupture of the aorta in all individuals with MVPS and MASS. Second, in
agreement with the deﬁnitions, we diagnosed MVPS and MASS only in
individuals with aortic sinus diameters b2 Z-scores where individuals
with MVPS exhibited mean diameters of 3.1 cm (2.2–3.7 cm) and with
MASS of 2.9 cm (2.1–3.6 cm) at baseline. Our patients were younger
than 50 years on average at the time of ﬁnal contact, and hence we
were unable to exclude that aortic events may appear and evolve later
in life. However, follow-up intervals and age at ﬁnal contact were simi-
lar across all groups, and therefore it appears justiﬁed to conclude that
the prognosis of aortic disease in MVPS and MASS is by far better than
in MFS.
Posterior MVP and bileaﬂet MVP were less frequent in MASS than
in the other syndromes. Thus, not the type of syndrome determines
the progression of MV disease, but rather echocardiographic charac-
teristics such as enlarged LV diameters, moderate MV regurgitation
and MV ﬂail leaﬂet. Echocardiographic characteristics are well-
documented to predict progression of MV disease both in idiopathic
MVP [44,45], and in MFS-related MVP [22]. Hence, clinical events
in MVPS and MASS originate from MVP, where long-term prognosis
does not relate to a diagnostic sub-classiﬁcation as MVPS or as
MASS but rather to the echocardiographic features related to MV
disease.
Finally, NT-pro-BNP levels were assessed in 62 individuals (50%) of
our cohort. The results indicated that myocardial dysfunction was
present in MFS but not in MVPS and MASS. Interestingly, myocardial
dysfunction was unrelated to moderate MV regurgitation (odds
ratio = .999; 95% CI .998–1.001; P= .476). Myocardial dysfunction in
MFS is conﬁrmed by the literature [46,47], butwe did not ﬁnd previous-
ly reported data on myocardial function in MVPS and MASS.4.1. Study limitations
We provide the ﬁrst long-term experience with MVPS and MASS.
However, our cohort is unlikely to reﬂect a sample that is representative
of MVPs and MASS in the general population. Our study was retrospec-
tive, two different centers were involved, patients were selected based
on completeness of clinical and molecular data, and clinical event
rates were low. Therefore, we considered P-values as descriptive mea-
sures to indicate inhomogeneity between groups. Further, we found
no mutation in FBN1, TGFBR1 and TGFBR2 in any individual with MVPS
or MASS, but the etiology of these syndromes remains unknown. Due
to the retrospective nature of the study, not all echocardiographic fea-
tures were similarly well documented, which resulted in some missing
information as delineated in Table 1. Similarly, we report long-termout-
comes of MVPS and MASS but we do not provide echocardiographic
follow-up data on the progression of aortic diameter or MV disease. Fi-
nally, some of the differences between groups, such as lower systemic
scores, and smaller aortic root diameters in MVPS and MASS as com-
pared with MFS were integral to the deﬁnition of groups rather than
the results of our study. We should be aware that in MVPS and MASS
smaller aortic diameters at baselinemay result into aortic complications
later in life than in MFS.5. Conclusions
Our study provides evidence that MVPS and MASS are Marfan-like
syndromes with stability of aortic dilatation but with progression of
MV disease. Echocardiographic characteristics of MV predict progres-
sion of MV disease. The current nosology uses the number of systemic
Marfan-like features to distinct MVPS from MASS, but the number of
these features does not seem to have impact on clinical outcomes. Pro-
spective studies with longer follow-up seem warranted to validate
these ﬁndings.
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